

Research Report - Antibody

To
Dean's Office of the Medical Faculty
Transfer Department
Sarah Wittlich
Joseph-Stelzmann-Str. 20
50931 Köln

To be completed by university administration only

Date of Invention Disclosure: _____

Submission of complete document on: _____

Note of incompleteness on: _____

Signed and as PDF:
med-transfer@uni-koeln.de

Only send in sealed envelope with a note that it must only be opened by addressee!

Content:

- Part A: General information about the antibody
- Part B: Information about the originator(s)
- Part C: Description of the antibody
- Part D: Description of the market
- Part E: Declaration of the originator(s)
- Part F: Confirmation of the university
- Part G: Assignment PROvendis

Part A: General information about the antibody

[A1] Abbreviated designation of the antibody

--

[A2] Brief description of the antibody

--

[A3] When was the antibody generated? _____

[A4] Has a patent been filed for the antibody? Yes No

[A5] How many persons contributed to the generation of the antibody? _____

Please additionally complete B1 to B8 for each person!

Part B: Information about the originators

Please copy this page for each person who participated in the generation of the antibody, and fill out completely.

[B1] Name and address	
Family name	
First name	
Nationality	
Occupational title	
Official position	
Department/Institute/Company	

Business address	
Phone	
Fax	
Email	

Private address	
Phone	
Fax (if any)	
Email	

[B2] My contribution to the generation of the antibody was _____ % of all originators.

[B3] The antibody is related to my working field: Yes No

[B4] The antibody was generated in the context of my labour contract: Yes No

[B5] The antibody is significantly based on know-how and experience of the university (Department/Institute): Yes No

[B6] The antibody was generated as a result of instruction: Yes No

If yes, who has given the instructions? _____

**[B7] The antibody was generated as part of my
Doctoral-/Master-thesis (or any similar study work):** Yes No

[B8] Have third-party funds been used for the generation of the antibody?

[B8-1] The antibody was generated as part of a public funded project:
 DFG BMBF EU Other: _____
 My job has been financed from these project funds.
 I know the purpose of the project.

[B8-2] The antibody was generated in collaboration with partners:
 Partner: _____
 My job has been financed from this collaboration.
 I know the purpose of the collaboration.

[B8-3] No third-party funds have been used

Part C: Description of the antibody

[C1] Type

- monoclonal
 polyclonal

[C2] Species of antigen

- Human Mouse Rat Rabbit Sheep
 Goat Other _____

[C3] Characterization of the antigen

Name: _____

Number (e.g. UniProt, GenBank): _____

Synthetic peptide: _____

Modifications: _____

[C4] Indication

- disease/therapy
 research
 diagnostic

[C5] Antibody protein

- complete antibody Antibody-fragment (Fab/Fab2/nanobody)

Species: Human Mouse Rat Chicken Sheep Goat

Other: _____

Isotype: _____

Molecular weight: _____

Fusion partner (if any): _____

[C6] Interaction

Epitope: _____

Affinity (K-value): _____

Cross reaction with other proteins of same species? Yes No n.a.

If yes, please specify: _____

Cross reaction with same antigen of other species? Yes No n.a.

If yes, please specify:

- | | | | | |
|-------------------------------------|-------------------------------------|--------------------------------------|--|---------------------------------|
| <input type="checkbox"/> Human | <input type="checkbox"/> Mouse | <input type="checkbox"/> Rat | <input type="checkbox"/> Rabbit | <input type="checkbox"/> Sheep |
| <input type="checkbox"/> C. elegans | <input type="checkbox"/> Drosophila | <input type="checkbox"/> Yeast | <input type="checkbox"/> Micro-organisms | <input type="checkbox"/> Plants |
| <input type="checkbox"/> Xenopus | <input type="checkbox"/> Zebrafish | <input type="checkbox"/> Other _____ | | |

[C7] Production

Cell line

Which cell line/hybridoma is used? _____

Culture conditions: _____

Any special cultivation requirements (supplements etc.)? Yes No

If yes, please specify: _____

Are there certain purification steps of the antibody?

Yes No antibody is not purified/n.a.

If yes, please specify: _____

Yield: _____

Ascites

No ascites has been taken:

Production not recommended:

Ascites successfully produced:

Yield: _____ mg/ml after injection of _____ cells per host organism

Purification:

purifies affinity purified supernatant serum ascites

other: _____

Storage:

Buffer: _____

Comments: _____

[C8] Description of epitope targeting

_____	_____
_____	_____
_____	_____

[C9] References

--

[C10] The following documents are provided as attachments to this report:

_____	_____
_____	_____

[C11] Please characterize the antibody by key words:

English

_____	_____
_____	_____
_____	_____
_____	_____

German (if possible)

_____	_____
_____	_____
_____	_____

[C12] Publications concerning the antibody

--

Part D: Description of the market

[D1] Do you consider to use the antibody in an own company foundation?

Yes No

[D2] For which application is your antibody eligible?

[D3] Which company should be considered as licensee (or other form of exploitation)?

[D4] Which companies do you already have contact with?

[D5] Which persons or customers would have benefit from the antibody?

[D6] How do you rate the market potential of the antibody:

very high high average low

Part E: Declaration of the originators

I/we agree with the transmission of my/our private data (such as private address, nationality) for marketing the antibody.

I/we assure that the information made hereinbefore is complete and true, that I/we have contributed to the development of the antibody, and that to our best knowledge no further person besides those mentioned herein were involved in the development of the antibody.

1. _____

(Date) (Signature)

2. _____

(Date) (Signature)

3. _____

(Date) (Signature)

4. _____

(Date) (Signature)

5. _____

(Date) (Signature)

Part F: Confirmation of the university

[F1] The originator(s) is/are employees of the university:			
	First name	Family name	
1.			<input type="checkbox"/> Yes <input type="checkbox"/> No
2.			<input type="checkbox"/> Yes <input type="checkbox"/> No
3.			<input type="checkbox"/> Yes <input type="checkbox"/> No
4.			<input type="checkbox"/> Yes <input type="checkbox"/> No
5.			<input type="checkbox"/> Yes <input type="checkbox"/> No
6.			<input type="checkbox"/> Yes <input type="checkbox"/> No

[F2] Third party's rights have to be considered: Yes No

If yes, the following third party's rights need to be considered:

The following contracts/agreements concerning these rights are attached in copy:

 (Date) (Name) (Signature)

Part G: Assignment of PROvendis

The university herewith assigns PROvendis to review the aforementioned antibody, and in case of a positive evaluation with its commercialization.

Comments:

_____, _____
Date Place

Signature